Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Rosalyn A Juergens

Showing results (1-10 of 53) with videos related to

Pageof 6
Sort By:
Journal of the National Comprehensive Cancer Network : JNCCN|October 18, 2008
Combined modality therapy of esophageal cancerRosalyn A Juergens, Arlene Forastiere
Current Oncology (Toronto, Ont.)|December 13, 2021
The Price of Success: Immune-Related Adverse Events from Immunotherapy in Lung CancerCourtney H Coschi, Rosalyn A Juergens
Journal of the National Comprehensive Cancer Network : JNCCN|July 4, 2006
Adjuvant treatment in non-small cell lung cancer: Where are we now?Rosalyn A Juergens, Julie R Brahmer
American Society of Clinical Oncology Educational Book. American Society of Clinical Oncology. Annual Meeting|May 30, 2013
Aberrant epigenetic regulation: a central contributor to lung carcinogenesis and a new therapeutic targetRosalyn A Juergens, Charles M Rudin
Current Oncology (Toronto, Ont.)|January 26, 2024
Overcoming Resistance Mechanisms to Immune Checkpoint Inhibitors: Leveraging the Anti-Tumor Immune ResponseCourtney H Coschi, Rosalyn A Juergens
Oncology (Williston Park, N.Y.)|January 1, 2011
Bevacizumab in advanced lung cancer: in search of the right drug for the right patientTimothy F Burns, Rosalyn A Juergens
Current Oncology Reports|June 11, 2005
Adjuvant therapy for resected non-small-cell lung cancer: past, present, and futureRosalyn A Juergens, Julie R Brahmer
Frontiers in Oncology|April 22, 2017
Update on Programmed Death-1 and Programmed Death-Ligand 1 Inhibition in the Treatment of Advanced or Metastatic Non-Small Cell Lung CancerMarco A J Iafolla, Rosalyn A Juergens
Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer|March 5, 2017
Oncology care provider perspectives on exercise promotion in people with cancer: an examination of knowledge, practices, barriers, and facilitatorsMichelle Nadler, Daryl Bainbridge, Jennifer Tomasone, et al.
Current Oncology (Toronto, Ont.)|May 26, 2023
Immune-Checkpoint Induced Skin Toxicity Masked as Squamous Cell Carcinoma: Case Report on Mimickers of Dermatological Toxicity with PD-1 InhibitionSze Wah Samuel Chan, Rahul Shukla, Jennifer Ramsay, et al.
Pageof 6

Showing results (1-10 of 53) with videos related to

Sort By:
Pageof 6
Journal of the National Comprehensive Cancer Network : JNCCN|October 18, 2008
Combined modality therapy of esophageal cancerRosalyn A Juergens, Arlene Forastiere
Current Oncology (Toronto, Ont.)|December 13, 2021
The Price of Success: Immune-Related Adverse Events from Immunotherapy in Lung CancerCourtney H Coschi, Rosalyn A Juergens
Journal of the National Comprehensive Cancer Network : JNCCN|July 4, 2006
Adjuvant treatment in non-small cell lung cancer: Where are we now?Rosalyn A Juergens, Julie R Brahmer
American Society of Clinical Oncology Educational Book. American Society of Clinical Oncology. Annual Meeting|May 30, 2013
Aberrant epigenetic regulation: a central contributor to lung carcinogenesis and a new therapeutic targetRosalyn A Juergens, Charles M Rudin
Current Oncology (Toronto, Ont.)|January 26, 2024
Overcoming Resistance Mechanisms to Immune Checkpoint Inhibitors: Leveraging the Anti-Tumor Immune ResponseCourtney H Coschi, Rosalyn A Juergens
Oncology (Williston Park, N.Y.)|January 1, 2011
Bevacizumab in advanced lung cancer: in search of the right drug for the right patientTimothy F Burns, Rosalyn A Juergens
Current Oncology Reports|June 11, 2005
Adjuvant therapy for resected non-small-cell lung cancer: past, present, and futureRosalyn A Juergens, Julie R Brahmer
Frontiers in Oncology|April 22, 2017
Update on Programmed Death-1 and Programmed Death-Ligand 1 Inhibition in the Treatment of Advanced or Metastatic Non-Small Cell Lung CancerMarco A J Iafolla, Rosalyn A Juergens
Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer|March 5, 2017
Oncology care provider perspectives on exercise promotion in people with cancer: an examination of knowledge, practices, barriers, and facilitatorsMichelle Nadler, Daryl Bainbridge, Jennifer Tomasone, et al.
Current Oncology (Toronto, Ont.)|May 26, 2023
Immune-Checkpoint Induced Skin Toxicity Masked as Squamous Cell Carcinoma: Case Report on Mimickers of Dermatological Toxicity with PD-1 InhibitionSze Wah Samuel Chan, Rahul Shukla, Jennifer Ramsay, et al.
Pageof 6